None listed
Conditions
Brief summary
one major complication of electroconvulsive therapy (ECT) is the potential for temporary mild to moderate cognitive impairment. Memantine (a NMDA antagonist agent) has a beneficial effect on cognition in patients with moderate to severe Alzheimer ’s disease. The purpose of this study was to assess the effectiveness of Memantine 5mg/d in the prevention of cognitive impairments during ECT treatment. A prospective, double blind, placebo controlled trial included 40 patients underwent ECT will be done. Patients will randomly select to receive either memantine 5 mg/d or a placebo. Drug or placebo started the day before doing ECT and continue throughout the fourth course of ECT. An objective measure of cognitive function is Modified Mental Status Examination (MMSE) and will be performed pre-ECT and post-ECT. Finally score of MMSE before and after ECT will be compare.
Interventions
Administration of oral memantine 5 mg daily that will be start the day before doing ECT. Adherence monitoring will be done by counting tablet return by patients.Meantime 5mg daily continue throughout the fourth course of ECT (last dose at fourth course of ECT)
Sponsors
Mohammad Abbasinazari
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
All patients between 18-60 years old undergoing ECT in the psychosomatic ward of Taleghani hospital(Tehran, Iran) with informed consent
Exclusion criteria
patients with renal failure or hepatic failure, those with cardiac block, patients using medications with anticholinergic or NMDA(N-methyl D aspartate) antagonistic effect,pregnant and brearstfeeding women
Outcome results
None listed